학술논문
A Phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors
Document Type
Article
Author
Source
In: Clinical Cancer Research . (Clinical Cancer Research, 15 February 2015, 21(4):730-738)
Subject
Language
English
ISSN
15573265
10780432
10780432